ResearcherFudan UniversityActive in the last 2 years
Weilin Mao
Matched on ORCID iD 0000-0002-9872-2671; OpenAlex author ID A5101584194. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper
Papers 5
- Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. Co-author DOI 10.1136/jitc-2023-008694↗
- NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Co-author DOI 10.1007/s10620-022-07671-w↗
- Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. Co-author DOI 10.1080/15384101.2021.2014254↗
- PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. First author DOI 10.7150/jca.61498↗
- Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. Co-author DOI 10.2147/ott.s176101↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yefei Rong · 4 shared papers, 2019–2023 · strength 0.63
- Paper NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1… DOI 10.1007/s10620-022-07671-w↗
- Paper Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdow… DOI 10.1080/15384101.2021.2014254↗
- Paper PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. DOI 10.7150/jca.61498↗
- Tiantao Kuang · 3 shared papers, 2022–2023 · strength 0.53
- Paper NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1… DOI 10.1007/s10620-022-07671-w↗
- Paper Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdow… DOI 10.1080/15384101.2021.2014254↗
- Paper PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. DOI 10.7150/jca.61498↗
- Wenhui Lou · 3 shared papers, 2019–2024 · strength 0.47
- Paper Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdow… DOI 10.1080/15384101.2021.2014254↗
- Paper Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. DOI 10.1136/jitc-2023-008694↗
- Paper Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. DOI 10.2147/ott.s176101↗
- Xuefeng Xu · 3 shared papers, 2019–2023 · strength 0.44
- Paper NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1… DOI 10.1007/s10620-022-07671-w↗
- Paper PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. DOI 10.7150/jca.61498↗
- Paper Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. DOI 10.2147/ott.s176101↗
- Jianang Li · 2 shared papers, 2022–2023 · strength 0.38
- Paper NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1… DOI 10.1007/s10620-022-07671-w↗
- Paper Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdow… DOI 10.1080/15384101.2021.2014254↗
- Wenhui Lou · 2 shared papers, 2022–2023 · strength 0.34
- Dansong Wang · 2 shared papers, 2022–2023 · strength 0.34
- Wenchuan Wu · 2 shared papers, 2022–2024 · strength 0.34
- Dayong Jin · 2 shared papers, 2019–2022 · strength 0.25
- Lei Zhang · 1 shared paper, 2023 · strength 0.19
- Lei Zhang · 1 shared paper, 2022 · strength 0.19
- Ning Pu · 1 shared paper, 2024 · strength 0.18
- Jiande Han · 1 shared paper, 2024 · strength 0.18
- Hanlin Yin · 1 shared paper, 2024 · strength 0.18
- Qiangda Chen · 1 shared paper, 2024 · strength 0.18
- Joseph R. Habib · 1 shared paper, 2024 · strength 0.18
- Taochen He · 1 shared paper, 2024 · strength 0.18
- Huanyu Wang · 1 shared paper, 2022 · strength 0.15
- Lei Zhang · 1 shared paper, 2022 · strength 0.15
- Lei Zhang · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.